Introducing Pulsara Intelligence: AI Tools for Streamlined Emergency Care
In fast-paced clinical settings, documentation often competes with communication and patient care. Pulsara’s mission is to give healthcare workers an...
1 min read
Brittney Nelson, BSN, RN, SCRN
:
Apr 11, 2017

“I think it will help you as a doctor to know you’re doing a treatment not only for 3 months, but that the treatment benefit is going to last for at least 2 years,” said Yvo Roos, MD. “It’s going to help you be more convincing to the relatives that you’re doing the right thing, that you’re doing something that’s really going to help them."
The above quote is in reference to new long-term followup data published as of April 6th, 2017, which now confirms and extends the outcomes of the MR CLEAN endovascular therapy trial in acute ischemic stroke patients. The results show that 1 out of every 3 patients treated with catheter based intervention are returning home to care for themselves within 3 months and these results are durable up to 2 years! Read the full details of the follow up data right here.
In fast-paced clinical settings, documentation often competes with communication and patient care. Pulsara’s mission is to give healthcare workers an...
September Recap The weather may (finally) be cooling off, but our autumn event season is bringing the heat. 12 down in September and another 12 on...
How an Arkansas hospital improved their door-to-needle benchmark success rates across the board and achieved a record treatment time of 18 minutes. ...